Table 2.
General characteristics of patients interventions
| Author | Teriparatide OR denosumab | Bisphosphonates | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Age (year) | BMI (kg/m2) | Intervention | No | Age (year) | BMI (kg/m2) | Intervention | ||||
| Anastasilakis | 22 | 65.4 | 28.2 | SC teriparatide (20 µg/day) | 22 | 64.7 | 28.1 | Oral risedronate (35 mg/week) | |||
| Body | 73 | 65 | 23.9 | SC teriparatide (40 µg/day) | 73 | 66 | 24.4 | Oral alendronate (10 mg/day) | |||
| Chiba | 46 | 71.7 | 23.4 | SC teriparatide (20 µg/day) | 40 | 71.9 | 23.1 | Oral alendronate (35 mg/week) | |||
| Cosman | 138 | 63.8 | 25.3 | SC teriparatide (20 µg/day) | 137 | 66.1 | 25.3 | Intravenous zoledronic acid (5 mg/year) | |||
| Finkelstein | 25 | 57 | 25.3 | SC teriparatide (40 µg/day) | 28 | 58 | 25.7 | Oral alendronate (10 mg/day) | |||
| Finkelstein | 20 | 65 | 24.9 | SC teriparatide (40 µg/day) | 29 | 64 | 25.6 | Oral alendronate (10 mg/day) | |||
| Hadji | 360 | 70.5 | 26.3 | SC teriparatide (20 µg/day) | 350 | 71.6 | 26.4 | Oral risedronate (35 mg/week) | |||
| Keaveny | 28 | 64.5 | 26.3 | SC teriparatide (20 µg/day) | 25 | 62.5 | 26.6 | Oral alendronate (1 0 mg/day) | |||
| Keaveny | 27 | 64.2 | 25.6 | SC teriparatide (20 µg/day) | 21 | 62.2 | 26.5 | Oral alendronate (10 mg/day) | |||
| Kendler | 680 | 72.6 | 26.9 | SC teriparatide (20 µg/day) | 680 | 71.6 | 21.7 | Oral risedronate (35 mg/week) | |||
| Li | 391 | 64.2 | 23.1 | SC teriparatide (20 µg/day) | 196 | 63.6 | 23.2 | Oral alendronate (70 mg/week) | |||
| Malouf-Sierra | 86 | 77.2 | _ | SC teriparatide (20 µg/day) | 85 | 76.4 | _ | Oral risedronate (35 mg/week) | |||
| McClung | 102 | 65.3 | 25.7 | SC teriparatide (20 µg/day) | 101 | 66.6 | 25.3 | Oral alendronate (10 mg/day) | |||
| Panico | 42 | 65 | 24.5 | SC teriparatide (20 µg/day) | 39 | 60 | 22.8 | Oral alendronate (70 mg/week) | |||
| Walker | 9 | 51.6 | 25.2 | SC teriparatide (20 µg/day) | 10 | 54 | 24.8 | Oral risedronate (35 mg/week) | |||
| Ji | 84 | 66.8 | 23.7 | SC teriparatide (20 µg/day) | 120 | 68.1 | 23.5 | Intravenous zoledronic Acid (5 mg/year) | |||
| Beck | 39 | 63 | 28.32 | SC denosumab (60 mg/6 month) | 38 | 63 | 27.39 | Oral alendronate (70 mg/week) | |||
| Brown | 594 | 64.1 | _ | SC denosumab (60 mg/6 month) | 595 | 64.6 | _ | Oral alendronate (70 mg/week) | |||
| Iseri | 24 | 71.3 | 19.9 | SC denosumab (60 mg/6 month) | 24 | 71.5 | 20.7 | Intravenous alendronate (900 µg/4 week) | |||
| Lewiecki | 319 | 62.3 | _ | SC denosumab (60 mg/6 month) | 47 | 62.8 | _ | Oral alendronate (70 mg/week) | |||
| McClung | 47 | 63.1 | 15.7 | SC denosumab (60 mg/6 month) | 47 | 62.8 | 13.7 | Oral alendronate (70 mg/week) | |||
| Nakamura | 472 | 69.9 | 22.6 | SC denosumab (60 mg/6 month) | 242 | 70.2 | 22.3 | Oral risedronate (35 mg/week) | |||
| Nakura | 51 | 69.9 | 23.2 | SC denosumab (60 mg/6 month) | 52 | 68.3 | 22.5 | Oral risedronate (17.5 mg/week) | |||